Close Menu

licensing agreement

The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.

The drug giant will be responsible for globally developing and commercializing the compound, called Erso, currently in preclinical development.

The global license extends to all indications under evaluation, though Rain will focus on exploring the activity of milademetan in MDM2-amplified or -overexpressing cancers.

Patients whose tumor cells express certain levels of the protein TEM 8 may be more likely to benefit from Seneca's investigational agent, according to MSK-led research.

Through a licensing agreement with Drexel, Rain will support the ongoing development of RAD52 inhibitors for patients with homologous recombination deficient cancers.

The partners are hoping to leverage their expertise to advance drugs with a novel mechanism of action that will target a broader range of RAS mutations.

Qualigen Therapeutics will acquire intellectual property rights to the family of RAS-targeting small molecules and pay royalties to Louisville upon commercialization.

This is the fifth neratinib approval for Puma's licensing partner STA, which is also commercializing the drug in Australia, New Zealand, Singapore, and Brunei.

Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.

The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.